The HIV-1 integrase-LEDGF allosteric inhibitor MUT-A: resistance profile, impairment of virus maturation and infectivity but without influence on RNA packaging or virus immunoreactivity - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Retrovirology Année : 2017

The HIV-1 integrase-LEDGF allosteric inhibitor MUT-A: resistance profile, impairment of virus maturation and infectivity but without influence on RNA packaging or virus immunoreactivity

Laia Miralles
  • Fonction : Auteur
  • PersonId : 1022619
Julie Brias
  • Fonction : Auteur
  • PersonId : 949381
Francis Chevreuil
  • Fonction : Auteur
  • PersonId : 949376
Sophie Chasset
  • Fonction : Auteur
  • PersonId : 949374
Benoit Ledoussal
  • Fonction : Auteur
  • PersonId : 949386
Luzia Mayr
  • Fonction : Auteur
  • PersonId : 1022621
Felipe García
  • Fonction : Auteur
  • PersonId : 1022622
José Gatell
  • Fonction : Auteur
  • PersonId : 1022623
Christiane Moog
  • Fonction : Auteur
  • PersonId : 920434
Montserrat Plana
  • Fonction : Auteur
  • PersonId : 1022626

Résumé

BACKGROUND: HIV-1 Integrase (IN) interacts with the cellular co-factor LEDGF/p75 and tethers the HIV preintegration complex to the host genome enabling integration. Recently a new class of IN inhibitors was described, the IN-LEDGF allosteric inhibitors (INLAIs). Designed to interfere with the IN-LEDGF interaction during integration, the major impact of these inhibitors was surprisingly found on virus maturation, causing a reverse transcription defect in target cells. RESULTS: Here we describe the MUT-A compound as a genuine INLAI with an original chemical structure based on a new type of scaffold, a thiophene ring. MUT-A has all characteristics of INLAI compounds such as inhibition of IN-LEDGF/p75 interaction, IN multimerization, dual antiretroviral (ARV) activities, normal packaging of genomic viral RNA and complete Gag protein maturation. MUT-A has more potent ARV activity compared to other INLAIs previously reported, but similar profile of resistance mutations and absence of ARV activity on SIV. HIV-1 virions produced in the presence of MUT-A were non-infectious with the formation of eccentric condensates outside of the core. In studying the immunoreactivity of these non-infectious virions, we found that inactivated HIV-1 particles were captured by anti-HIV-specific neutralizing and non-neutralizing antibodies (b12, 2G12, PGT121, 4D4, 10-1074, 10E8, VRC01) with efficiencies comparable to non-treated virus. Autologous CD4+ T lymphocyte proliferation and cytokine induction by monocyte-derived dendritic cells (MDDC) pulsed either with MUT-A-inactivated HIV or non-treated HIV were also comparable. CONCLUSIONS: Although strongly defective in infectivity, HIV-1 virions produced in the presence of the MUT-A INLAI have a normal protein and genomic RNA content as well as B and T cell immunoreactivities comparable to non-treated HIV-1. These inactivated viruses might form an attractive new approach in vaccine research in an attempt to study if this new type of immunogen could elicit an immune response against HIV-1 in animal models.
Fichier principal
Vignette du fichier
s12977-017-0373-2.pdf (1.42 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Loading...

Dates et versions

inserm-02409731 , version 1 (13-12-2019)

Identifiants

Citer

Céline Amadori, Yme Ubeles van Der Velden, Damien Bonnard, Igor Orlov, Nikki van Bel, et al.. The HIV-1 integrase-LEDGF allosteric inhibitor MUT-A: resistance profile, impairment of virus maturation and infectivity but without influence on RNA packaging or virus immunoreactivity. Retrovirology, 2017, 14 (1), pp.50. ⟨10.1186/s12977-017-0373-2⟩. ⟨inserm-02409731⟩
208 Consultations
181 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More